Boston Scientific Corporation (BSX) 의 후행 P/E는 31.7, 선행 P/E 18.7. 후행 이익수익률은 3.16%, 선행 이익수익률 5.35%. PEG 0.57 (Peter Lynch 저평가 ≤1.0). 그레이엄 넘버는 $26.90.
이 페이지에서 입증된 기준:
SharesGrow 종합 점수: 80/100 5/7 개 기준 통과.
| Year | P/E (TTM) | PEG 비율 | P/B 비율 | P/S 비율 | 배당 수익률 |
|---|---|---|---|---|---|
| 2016 | 84.6 | -0.35 | 4.36 | 3.50 | - |
| 2017 | 326.6 | -4.72 | 4.84 | 3.75 | - |
| 2018 | 29.2 | 0.02 | 5.59 | 4.97 | - |
| 2019 | 13.4 | 0.07 | 4.53 | 5.86 | - |
| 2020 | -621.1 | 6.07 | 3.32 | 5.14 | 0.05% |
| 2021 | 58.1 | -0.06 | 3.63 | 5.08 | 0.09% |
| 2022 | 94.8 | -2.69 | 3.77 | 5.22 | 0.08% |
| 2023 | 52.7 | 0.37 | 4.36 | 5.90 | 0.03% |
| 2024 | 70.9 | 4.27 | 6.04 | 7.85 | - |
| 2025 | 48.9 | 0.88 | 5.82 | 7.03 | - |
| Year | EPS (희석) | 매출 | 순이익 | 순이익률 |
|---|---|---|---|---|
| 2016 | $0.25 | $8.39B | $347M | 4.1% |
| 2017 | $0.07 | $9.05B | $104M | 1.1% |
| 2018 | $1.19 | $9.82B | $1.67B | 17% |
| 2019 | $3.33 | $10.74B | $4.7B | 43.8% |
| 2020 | $-0.10 | $9.91B | $-140M | -1.4% |
| 2021 | $0.69 | $11.89B | $1.04B | 8.8% |
| 2022 | $0.45 | $12.68B | $698M | 5.5% |
| 2023 | $1.07 | $14.24B | $1.59B | 11.2% |
| 2024 | $1.25 | $16.75B | $1.85B | 11.1% |
| 2025 | $1.94 | $20.07B | $2.89B | 14.4% |
| Year | EPS (평균) | EPS 범위 | 매출 (평균) | 매출 범위 | 애널리스트 수 |
|---|---|---|---|---|---|
| 2026 | $3.47 | $3.42 – $3.51 | $22.25B | $22.15B – $22.69B | 18 |
| 2027 | $3.91 | $3.79 – $3.98 | $24.59B | $24.25B – $25.19B | 18 |
| 2028 | $4.44 | $4.06 – $4.92 | $27.09B | $27.03B – $27.16B | 4 |
| 2029 | $4.98 | $4.91 – $5.13 | $29.74B | $29.42B – $30.42B | 2 |
| 2030 | $5.61 | $5.53 – $5.78 | $33.07B | $32.71B – $33.83B | 2 |
